Ribometrix is a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases. The Ribometrix team leverages its world-leading expertise in 3D structural analysis of RNA to drive its discovery platform, drawing on technologies invented in the laboratory of Ribometrix scientific founder Kevin Weeks, Ph.D. Ribometrix is headquartered in Durham, North Carolina.


Latest News Entry
Ribometrix Announces $30 Million Series A Funding to Advance Pipeline of RNA-Targeting Small Molecule Therapies

• Funds will allow for advancement of lead molecules and expand its powerful platform for small molecule discovery based on 3D structural analysis of RNA
• Financing led by M Ventures, joined by a syndicate of new and existing investors

all portfolio news